Enterprise Value
4.948M
Cash
53.25M
Avg Qtr Burn
-11.32M
Short % of Float
0.06%
Insider Ownership
0.40%
Institutional Own.
39.61%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GB0139 (inhaled galectin-3 inhibitor) Details Fibrosis, Pulmonary fibrosis, Lung disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2/3 Data readout | |
GB1211 (oral galectin-3 inhibitor) Details Non-small cell lung carcinoma, Fibrosis, Cancer | Phase 2 Update | |
GB2064 (oral LOXL2 inhibitor) Details Fibrosis, Myelofibrosis | Phase 2a Data readout | |
GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details Non-small cell lung carcinoma, Cancer, Fibrosis | Phase 2a Interim update |